These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23718922)

  • 21. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent.
    Wilmot HV; Gray E
    Haemophilia; 2018 Sep; 24(5):e363-e368. PubMed ID: 30051554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
    Guy S; Kitchen S; Maclean R; Van Veen JJ
    Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methodical aspects of blood coagulation measurements in birds applying commercial reagents--a pilot study.
    Guddorf V; Kummerfeld N; Mischke R
    Berl Munch Tierarztl Wochenschr; 2014; 127(7-8):322-7. PubMed ID: 25080826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lyophilised plasmas for one-stage determination of factor VIII.
    Sikorová J; Vorlová Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A proposed model to monitor heparin therapy using the concentrated thrombin time which allows standardisation of reagents and improved estimation of heparin concentrations.
    Ray MJ; Perrin EJ; Smith IR; Hawson GA
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):515-21. PubMed ID: 8874861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of factor VIII:C and factor IX activity in plasmas of haemophilic dogs on the activated partial thromboplastin time measured with two commercial reagents.
    Mischke R
    Haemophilia; 2000 May; 6(3):135-9. PubMed ID: 10792470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significantly different coagulation factor activities underlying the variability of 'normal' activated partial thromboplastin time.
    Park KJ; Kwon EH; Ma Y; Park IA; Kim SW; Kim SH; Kim HJ
    Blood Coagul Fibrinolysis; 2012 Jan; 23(1):35-8. PubMed ID: 22027757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Assessment of Factor VIII Activity by Template Matching Utilizing Weighted Average Parameters from Comprehensive Clot Waveform Analysis.
    Shimonishi N; Ogiwara K; Oda Y; Kawabe T; Okazaki S; Shima M; Nogami K
    Thromb Haemost; 2021 Feb; 121(2):164-173. PubMed ID: 32828071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance characteristics of a new synthetic APTT reagent.
    Ts'ao C; Neofotistos D; Oropeza M; Rogan M; Santos M
    Clin Lab Haematol; 1998 Oct; 20(5):307-13. PubMed ID: 9807679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experimental quality assessment of APTT-control reagent kits in the study of heparin-containing plasma in therapeutic ranges].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 Apr; (4):39-41. PubMed ID: 21735680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
    Wilmot HV; Rakowski K; Gray E
    Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental quality assessment of APTT-control reagent kits in the study of plasma with varying Factor VIII activity].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 May; (5):31-3. PubMed ID: 21786611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants.
    Denis-Magdelaine A; Flahault A; Verdy E
    Haemostasis; 1995; 25(3):98-105. PubMed ID: 7607585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
    Francis JL; Hursting MJ
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
    Marlar RA; Bauer PJ; Endres-Brooks JL; Montgomery RR; Miller CM; Schanen MM
    Am J Clin Pathol; 1984 Oct; 82(4):436-9. PubMed ID: 6475840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.